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13C Pyruvate Transport Across the 
Blood-Brain Barrier in Preclinical 
Hyperpolarised MRI
Jack J. Miller  1,2,3, James T. Grist  4, Sébastien Serres5,6, James R. Larkin  5, Angus Z. Lau7,8, 
Kevin Ray5,9, Katherine R. Fisher  10, Esben Hansen11, Rasmus Stilling Tougaard11,12, 
Per Mose Nielsen11, Jakob Lindhardt11, Christoffer Laustsen  11, Ferdia A. Gallagher4, 
Damian J. Tyler1,3 & Nicola Sibson5
Hyperpolarised MRI with Dynamic Nuclear Polarisation overcomes the fundamental thermodynamic 
limitations of conventional magnetic resonance, and is translating to human studies with several early-
phase clinical trials in progress including early reports that demonstrate the utility of the technique 
to observe lactate production in human brain cancer patients. Owing to the fundamental coupling of 
metabolism and tissue function, metabolic neuroimaging with hyperpolarised [1-13C]pyruvate has the 
potential to be revolutionary in numerous neurological disorders (e.g. brain tumour, ischemic stroke, 
and multiple sclerosis). Through the use of [1-13C]pyruvate and ethyl-[1-13C]pyruvate in naïve brain, 
a rodent model of metastasis to the brain, or porcine brain subjected to mannitol osmotic shock, we 
show that pyruvate transport across the blood-brain barrier of anaesthetised animals is rate-limiting. 
We show through use of a well-characterised rat model of brain metastasis that the appearance of 
hyperpolarized [1-13C]lactate production corresponds to the point of blood-brain barrier breakdown 
in the disease. With the more lipophilic ethyl-[1-13C]pyruvate, we observe pyruvate production 
endogenously throughout the entire brain and lactate production only in the region of disease. In the 
in vivo porcine brain we show that mannitol shock permeabilises the blood-brain barrier sufficiently 
for a dramatic 90-fold increase in pyruvate transport and conversion to lactate in the brain, which is 
otherwise not resolvable. This suggests that earlier reports of whole-brain metabolism in anaesthetised 
animals may be confounded by partial volume effects and not informative enough for translational 
studies. Issues relating to pyruvate transport and partial volume effects must therefore be considered 
in pre-clinical studies investigating neuro-metabolism in anaesthetised animals, and we additionally 
note that these same techniques may provide a distinct biomarker of blood-brain barrier permeability in 
future studies.
Hyperpolarisation methods overcome the fundamental Boltzmann limitation on the signal-to-noise ratio of 
Magnetic Resonance (MR) experiments through the exogenous creation of nuclear polarisation. The introduction 
of the dissolution Dynamic Nuclear Polarisation (dDNP) method for metabolic imaging in vivo has generated 
a new field of metabolic imaging, in which 13C labelled metabolites are hyperpolarised at cryogenic tempera-
tures (~0.8 K), rapidly melted, and introduced into a living system, with their subsequent metabolic behaviour 
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quantified through MR1–3. There are numerous distinct properties that an injectable hyperpolarised probe must 
possess in order to be of biomedical utility: a long nuclear T1, glassing ability, and miscibility with commonly-used 
electronic free radicals are required from a technical perspective, whereas minimal toxicity, rapid vascular trans-
portation, uptake across the plasma membrane, and subsequent cellular metabolism on the timescale of T1 are 
required for the probe to be of subsequent biomedical utility4–6.
Owing to its favourable nuclear properties and its metabolic location at the end of glycolysis and entrance to 
the TCA cycle, hyperpolarised [1-13C]pyruvate is currently in the process of transitioning to the clinic as a pow-
erful probe for the diagnosis of disease and quantification of its response to treatment. Following dissolution and 
injection, hyperpolarised [1-13C]pyruvate is transported through the body by the systemic circulation prior to its 
active transport into cells through proton-coupled monocarboxylate transporters (MCTs), particularly MCT-17, 
and its subsequent cytosolic or mitochondrial metabolism, all within the lifetime of the hyperpolarised experi-
ment. Uniquely in the brain, MCT-1 is expressed at both the luminal and abluminal membranes of the endothelial 
cells comprising the Blood-Brain Barrier (BBB), facilitating pyruvate transport across the blood brain barrier8,9.
In the heart, hyperpolarised [1-13C]pyruvate has been shown to be of utility in monitoring myocardial ischae-
mia4,10, in visualising the pathogenesis of heart failure11, and other cardiac pathologies. Owing to rapid vascular 
transport and a high metabolic demand, it is possible to dynamically resolve cardiac metabolism at comparatively 
high spatial and temporal resolution in rodents12,13, pigs14–19, and, recently, humans20. Likewise, hyperpolarized 
[1-13C]pyruvate has been used to probe renal metabolism in pathophysiology such as diabetes and following 
acute kidney injury21–25; and physiological hepatic metabolism in the fasted and fed states26, after consuming 
alcohol27, and in hepatocarcinoma28,29. In the heart, kidney and liver, hyperpolarised [1-13C]pyruvate metab-
olism can therefore be spatially and temporally resolved with a good signal-to-noise ratio at a physiologically 
relevant spatial resolution, and addresses pertinent biological and medical questions following the clear uptake 
and metabolism of the probe. In this work, we quantitatively assess the metabolism of [1-13C]pyruvate and ethyl-
[1-13C]pyruvate in the brain in comparison to other organs, in the context of the metabolic dysregulation present 
in cancer.
As one of the hallmarks of cancer is a profound shift away from oxidative metabolism towards aerobic glyco-
lysis, deemed the Warburg effect30, DNP with hyperpolarized [1-13C]pyruvate is uniquely positioned to quantify 
real-time exchange of the injected probe into [1-13C]lactate. Consequently, amongst other situations, the tech-
nique has been used extensively to study tumour metabolism in cell suspensions in vitro31,32, in xenografts33,34, 
as well as endogenous or spontaneously arising disease models such as the TRAMP mouse model of prostate 
cancer35–37. Furthermore, as the apparent lactate label exchange rate correlates with tumour aggressiveness and 
hence prognosis38, the key role of metabolism within tumour cells means that therapeutic interventions have been 
shown to substantially alter the apparent flux of [1-13C]pyruvate to [1-13C]lactate after radiotherapy39,40 or chemo-
therapy38,41–43 prior to a concomitant reduction in tumour volume as visualised by MR, even in the presence of 
pseudo-progression. Consequently, the initial human experiences of hyperpolarised pyruvate were performed in 
biopsy-proven prostate cancer patients, with the metabolic signature prospectively predicting bilateral disease in 
one instance44. Following the improved accessibility of the technique to other sites, further human studies have 
been undertaken and report on the feasibility of the technique for imaging lactate production in human brain45,46.
Metabolic alterations are additionally implicated in a large number of relevant and prevalent neurological 
disorders, such as increased lactate detected via 1H spectroscopy in multiple sclerosis lesions47, in experimental 
models of Parkinson’s disease48, in Alzheimer’s disease patients49, following traumatic brain injury50, in ischaemic 
stroke51,52 (correlating with the degree of neuronal loss53), and in leukoencephalopathy following heroin usage54. 
In stark contrast to the wide range of potential indications for the utility of hyperpolarised [1-13C]pyruvate imag-
ing in neurology, there remains a small, but growing body of work where hyperpolarisation techniques have been 
applied to probe neurological metabolism in vivo. Previous work in the brain with hyperpolarized compounds 
has almost exclusively examined the healthy brain in animals from rodents55,56 to simians57, and predominantly 
one pathology: experimental models of primary brain cancer, typically glioblastoma multiforme58, as well as one 
early study in stroke59. In primary brain cancer, both [1-13C]pyruvate, [2-13C]pyruvate58 and ethyl-[1-13C]pyru-
vate have all been used to probe metabolism in naïve brain21,60–62 compared to contralateral large diffuse glioma63, 
and the hyperpolarized lactate flux has been shown to be substantially reduced following radiotherapy64, useful in 
reporting on the IDH-1 status of the disease65. Likewise, inspired by thermal equilibrium studies, hyperpolarised 
13C -acetate has been infused into the rodent brain and its arrival observed. However, minimal subsequent entry 
into the TCA cycle was observed with 2-oxoglutarate at the limit of detection after acquisition with a large voxel 
volume and the addition of data from multiple animals66–68. Similarly, parahydrogen-induced hyperpolarized 
succinate has been utilised as a probe of primary brain cancer69, and it was noted that succinate was not trans-
ported sufficiently rapidly to be of utility beyond that of perfusion imaging, with no metabolic products being 
spectroscopically observed.
One of the defining features of later stage brain tumours is that the blood-brain barrier (BBB) has become 
permeabilised by dysregulated angiogenesis, mechanical disruption and inflammation, mediated by factors such 
as vascular endothelial growth factor (VEGF), brain angiogenesis inhibitor-1, and NF-κβ, amongst others70,71. 
This permeabilisation is pathological in nature, but enables the non-selective diffusion of small molecules into 
the brain and, hence, may increase the visibility of tumour burden to hyperpolarised imaging. In contrast to 
primary tumours, metastatic disease in the brain initiates through the adhesion and extravasation of tumour 
cells through the cerebral endothelium, with perivascular growth fed by diffusion. Continued growth leads to 
invasion of the brain parencheyma, which is unsustainable through diffusion alone and leads to angiogenesis. 
It is this angiogenesis, along with the bulk effects of tumour growth which leads to compromise of the BBB, 
and corresponds to a diffuse, metastatic phenotype in which the disruption of the BBB as visualised by clinical 
gadolinium-enhanced MR imaging corresponds to a significant tumour burden, which is associated with an 
exceptionally poor prognosis72.
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Given conflicting reports in the literature about the degree of transport of hyperpolarized pyruvate across the 
blood-brain barrier in naive and diseased brain in animals73–75, we sought to investigate, and provide bounded 
lower limits on, the kinetics of pyruvate transport in the anaesthetised animal brain. As clinically translating 
hyperpolarisation methods have shown a substantially different metabolic signature from the anaesthetised ani-
mal, we wished to investigate the effect of BBB transport on hyperpolarised [1-13C]pyruvate experiments and 
determine if the probe is unambiguously metabolised in the brain parenchyma. Moreover, should that be the case, 
we then hypothesised that it may be possible to resolve cancer that had metastasised to the brain early, through 
its metabolic phenotype, prior to the point of angiogenesis, which describes a typical animal study in which the 
technique may be used. We were explicitly mindful of the potentially confounding effects of the large hyperpo-
larised signal present in the vasculature, predisposition of MR imaging techniques to partial volume effects, and 
high cerebrovascular perfusion.
Results
Rodent brain hyperpolarised [1-13C]pyruvate MRS. We initially performed slice-selective hyperpo-
larised [1-13C]pyruvate MRS weekly on female BD-IX rats following the induction of a well-characterised intrac-
erebral model of breast carcinoma brain metastases using ENU-1564 cells over a four-week period, with visible 
disruption of the BBB present at approximately week three. Slice-selective spectra were obtained from both the 
ipsilateral and contralateral site of injection. The volume of leaking tumour was calculated from T1-weighted MRI 
pre/post gadolinium contrast (Fig. 1A).
Figure 1. Hyperpolarised [1-13C]pyruvate and a model of cancer metastasis to the brain. (A) Three weeks 
after model induction via IC injection, the presence of blood-brain barrier disruption is visible via gadolinium 
enhanced T1 weighted MRI, shown prior to (i) and post (ii) gadolinium administration, with the difference 
clearly revealing the region of disease (iii). The two spectroscopic slices chosen are additionally shown; scale 
bar 20 mm. (B) Representative ipsilateral spectrum acquired from the region of disease, with lactate, pyruvate 
hydrate, alanine and bicarbonate visible following the infusion of hyperpolarised [1-13C]pyruvate. (C) 
Immunohistochemical staining of the tumour in (A) reveals the presence of disease near the injection site, (i) 
here occupying approximately a 3.6 mm3 area within the striatum. (ii) Cells with a metastatic phenotype can be 
seen growing along the perivascular niche, which express (iii) TNF receptor I along the inside of the capillary 
bed in the region of disease (arrow; brown). (D) Despite the histologically-confirmed presence of disease, we 
did not detect a significant difference in the lactate-to-pyruvate ratio at any time points between the affected and 
control hemispheres of the brain although the ratio decreased over time. TNF administration likewise did not 
significantly alter the lactate-to-pyruvate ratio observed. (E) After fitting to a pseudo-first-order kinetic model, 
we found that the observed lactate/pyruvate ratio correlated significantly and positively with the returned rate 
constant (Spearman’s ρ ≈ 0.9; regression line shown). (F) In contrast to previously published work, and our 
expectations, we did not observe any significant correlation of apparent lactate production with tumour volume. 
(G) In culture, however the ENU-1564 cell line injected was highly glycolytic and comparable to other reported 
highly glycolytic cell lines.
www.nature.com/scientificreports/
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We could resolve metabolism in the anaesthetised brain, with the detection of all peaks aside from carbon 
dioxide, including bicarbonate (Fig. 1B). However, the total lactate/pyruvate ratio was not significantly differ-
ent between ipsilateral and contralateral hemispheres despite the presence of metastases as confirmed by his-
tology (Fig. 1C) even at the final time-point (p = 0.7; Fig. 1D). As reported previously, we have found that the 
pseudo-first order rate constant kLac→Pyr was highly correlated with the lactate/pyruvate ratio (Fig. 1E)76. The 
lactate/pyruvate ratio was significantly reduced over time (p = 0.0037 via an anova by linear mixed effects mod-
elling), which we believe to be consistent with an immune response following surgery, given that M1 monocytes 
and macrophages are highly glycolytic and produce a significant hyperpolarised lactate signal77. However, the 
subsequent decrease in lactate/pyruvate ratio over time may also show the later induction of an anti-inflammatory 
M2 phenotype, known to utilise fatty acid oxidation to fuel their metabolic needs78. Unexpectedly, no significant 
correlation was observed between the lactate/pyruvate ratio and tumour volume (Fig. 1F).
To assess the effect of physiologically permeabilising the blood-brain barrier, the pleiotropic cytokine TNF 
was injected IV two hours prior to spectroscopy at all but the “Week 0” timepoint. TNF administration has 
previously been shown to selectively permeabilise the blood-brain barrier in the region of metastatic disease via 
Gd-contrast and radio-labelled trastuzumab79, and has reported clinical use in limb-sparing surgery to improve 
chemotherapeutic uptake via direct arterial perfusion80. Thus, we hypothesised that the kinetics of hyperpolarised 
pyruvate transport and metabolism may change within the tumour-bearing hemisphere when TNF was admin-
istered. However, no significant differences were observed in pyruvate-lactate exchange, time-to-peak pyruvate 
or any other kinetic parameters in either ipsilateral or contralateral hemispheres following TNF administration, 
despite the immunohistochemical increased presence of endothelial TNF receptor 1 in the perivascular niche in 
the region of disease (Fig. 1C,D).
To provide a quantitative estimate for what we believe would be the lowest detectable tumour size visible to 
the technique, we cultured both the ENU-1564 cells injected in vivo and, additionally, two further cells lines; a 
very invasive human glioblastoma cell line reported to have a glycolytic and hypoxic profile81–83; and a metastatic 
mouse mammary carcinoma cell line, 4T184,85. We found that the lactate-to-pyruvate ratio of the three cell lines 
considered was consistent, with no significant difference between the groups (unadjusted p ≈ 0.96, 0.60, 0.62 via 
pairwise unequal variance t-tests), despite the differing origins and species of the originating cell lines, with a 
mean value of 1.3 ± 0.6 × 10−9 per cell for ENU cells Fig. 1G). Under these circumstances, we would expect to be 
statistically powered to detect differences on the order of 3 × 10−6 (α = 0.5 using Cohen’s d; calculation performed 
in R86–88), which is well within the range of inter-cell line variation in total lactate efflux reported by metabolo-
mic analysis89. We therefore note that these results would imply that under a set of assumptions detailed in the 
methods section, if perfusion differences were not limiting we would be approximately sensitive to tumours of 
diameter ≥1.5 mm3.
Rodent brain imaging with [1-13C]pyruvate and ethyl-[1-13C]pyruvate. To assess and determine 
the spatial localisation of the hyperpolarised signal received in the preceding MRS experiments, we performed 
longitudinal, three-dimensional, and high resolution spectral-spatial metabolic imaging on the naïve and dis-
eased rat brain with hyperpolarised [1-13C]pyruvate. We observed pyruvate localising in the vasculature in the 
rat head, predominantly in the region of the Circle of Willis, internal and external carotid arteries, and jugular 
veins. Interestingly, the small amount of 13C-lactate present at early time points was also observed approximately 
in the same vessels, at the detection limit of the technique in control animals (Fig. 2A). We observed pyruvate 
signal in both the dorsal and ventral great vessels, indicating that the surface receive coil used in this study was 
not limiting. Despite the early induction of metastatic disease in a known location, it was not possible to resolve a 
hyperpolarized 13C-lactate signal until after the disease was visible by conventional gadolinium-enhanced MR, at 
the point of BBB breakdown. At this point, hyperpolarised 13C-lactate was clearly visible localised to the region of 
disease (Fig. 2B). However, we found that the technique was not able to distinguish between diseased and healthy 
tissue prior to the point of blood-brain barrier breakdown, and the average lactate/pyruvate ratio in a region of 
interest around the injection site drawn by a blinded operator did not show elevated lactate production (Fig. 2C).
We hypothesised therefore that transportation across the BBB was rate limiting, and precluded the detection 
of cancer through its metabolic phenotype prior to the point at which it would conventionally be visible. To test 
this hypothesis, we therefore used hyperpolarised ethyl-[1-13C]pyruvate, a lipophilic analogue of pyruvate that 
has previously been reported to cross the BBB with greater efficiency than pyruvate prior to its enzymatic conver-
sion into [1-13C]pyruvate through non-specific esterases61,90. We hyperpolarised ethyl-[1-13C]pyruvate with the 
electronic free radical AH111501 and MultiHance (gadobenate dimeglumine) to improve solubility and glassing 
properties, and reached a nuclear polarisation of ~39%, approximately ~70% of that of [1-13C]pyruvate under 
similar conditions. Preliminary spectroscopic investigations revealed that we could detect ethyl pyruvate with 
good SNR in the brain (c.f. Fig. 2D, whose peak SNR is 56 compared with a SNR of ~80 for Fig. 1B) and with 
temporal dynamics that were consistent with endogenous metabolic production of lactate (Fig. 2E).
When imaged with a spiral IDEAL sequence at 2 × 2 mm in-plane resolution we found that with the same 
receive hardware hyperpolarised ethyl-[1-13C]pyruvate produced [1-13C]pyruvate within the brain parenchyma 
that was not confined only to the location of the vasculature, but approximately uniformly across the brain as a 
whole (Fig. 2D). Across every animal scanned, the ethyl-[1-13C]pyruvate derived [1-13C]pyruvate map was quan-
titatively dissimilar from that obtained via hyperpolarised [1-13C]pyruvate injection alone (mean Jaccard index 
<0.03 ± 0.02). However, as for [1-13C]pyruvate, lactate derived from hyperpolarised ethyl-[1-13C]pyruvate was 
only visible at the same timepoint as BBB breakdown, and was again wholly constrained to the region of disease.
Naïve porcine brain imaging following intracarotid infusion of hyperpolarised [1-13C]pyru-
vate. To further investigate the potential utility of cerebral pre-clinical imaging, we injected 20 ml of hyperpo-
larised [1-13C]pyruvate prepared in the Spinlab polariser currently used in clinical studies and via an angiography 
www.nature.com/scientificreports/
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catheter directly into the internal carotid artery of anaesthetised healthy swine prior to metabolic imaging at 
6 × 6 × 55 mm3. We observed cerebral perfusion through the Circle of Willis, posterior, anterior and superior cer-
ebellar arteries, middle cerebral artery, and into the basilar arteries. A small amount of concomitant lactate pro-
duction was observed, but not specifically localised to the brain parenchyma. Bounded kinetic analysis revealed 
no exchange of pyruvate to lactate (c.f. Fig. 3A–C) within the brain, i.e. kp = kPyr→Lac = 0.
Porcine brain imaging following mannitol infusion. To osmotically disrupt the blood-brain barrier 
(BBB), anaesthetised swine were infused with mannitol via the previously placed intracerebral catheter, and 
Figure 2. Hyperpolarised [1-13C]pyruvate and ethyl-[1-13C]pyruvate imaging in rats. (A) Representative 
summed [1-13C]pyruvate and [1-13C]lactate volumes shown concatenated through the slice axis following  
[1-13C]pyruvate infusion. Pyruvate was seen perfusing in the approximate location of the Circle of Willis 
(CW) and the middle cerebral artery (MCA), along with the common carotid and the jugular vein (JV/CA). 
The observed lactate signal is of low SNR and approximately seen in the location of the Circle of Willis. Proton 
images are deliberately scaled to the same resolution as the hyperpolarized scan. (B) As above, but for a tumour-
bearing animal, shown here at day 36, together with gadolinium difference image. Lactate was observed in 
the tumour. The colour axis is as for A Both image stacks have a reconstructed resolution of 1 × 1 × 2 mm3. 
The regional lac/pyr ratio was not significantly different between control and affected animals, although it 
significantly reduced over time (p = 0.00795 via an anova upon linear mixed effects modelling). (D,E) Example 
summed spectrum and peak intensity timecourses from ethyl-[1-13C]pyruvate infusion, after 10 Hz exponential 
apodization and polynomial baseline correction. Downstream metabolites are clearly visible, with the exception 
of bicarbonate and CO2 which were not resolved. (F) In contrast to the predominantly vascular images of 
hyperpolarized [1-13C]pyruvate, ethyl-[1-13C]pyruvate freely diffuses into the brain, producing downstream 
pyruvate and lactate visible only in the region of disease.
www.nature.com/scientificreports/
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a further hyperpolarised [1-13C]pyruvate injection undertaken immediately. In stark contrast to experiments 
conducted in the presence of an intact BBB, we observed significant exchange of [1-13C]pyruvate to [1-13C]lac-
tate within the cerebrum as a whole, and in particular the proximal and rostral portions of the parietal lobe. 
Furthermore, kp was detected in the brain, see Figs 3D–F and 4A. We found that mannitol disruption did not 
impede hyperpolarised experiments, which occur on a timescale of approximately three minutes.
Within the mannitol-permeabilised brain the [1-13C]lactate to [1-13C]pyruvate ratio was significantly higher 
than that in the naïve brain (0.09 ± 0.02 vs 0.001 ± 0.001, respectively, p < 0.05, Cohen’s d effect size = 31). kp was 
also increased (0.012 ± 0.07 vs 0.002 ± 0.001, p < 0.05, effect size = 4.5), c.f. Fig. 4B,C. No [1-13C bicarbonate] was 
observed in the porcine brain in either case.
Discussion
There are a large number of neurological pathologies in which metabolism is dysregulated where hyperpolarised 
imaging may therefore be of direct utility. We initially wished to use longitudinal hyperpolarised [1-13C]pyruvate 
imaging to detect a rodent model of cancer metastasis to the brain by its metabolic phenotype before its direct 
detection via gadolinium enhanced MRI mediated by disruption of the BBB. We found that this was not possible 
by either spectroscopy or imaging: increased [1-13C]lactate signal was only detectable after the point of BBB dis-
ruption as assessed by direct proton imaging. We note that this does not preclude preclinical utility, e.g. through 
the use of the technique to monitor the response of disease to therapy, but we wished to provide a physiological 
interpretation for the low SNR of these imaging techniques compared to other organs, especially the heart, for 
which high-resolution temporal imaging can be readily obtained12,17,20. As a consequence, we therefore investi-
gated the effect of permeabilising the blood-brain barrier physiologically in the region of disease, in an attempt 
to increase pyruvate transport and hence apparent lactate production. We found that TNF did not significantly 
alter transport kinetics despite the histological presence of the receptor, and thus did not pursue its use further.
Our imaging experiments show clearly and reproducibly the appearance of [1-13C]pyruvate in the great ves-
sels on both sides of the rat head and neck, illustrating that the receive profile of the RF coil array would not be 
limiting for the detection of metabolites within the brain parenchyma. In naïve rats, we apparently observed 
lactate production within the great vessels also, which may reflect either the glycolytic nature of red blood cells, or 
alternatively the efflux of hyperpolarised [1-13C]lactate from other organs, such as the liver91. We note that while 
we detected bicarbonate spectroscopically, we were not able to image its production. Additionally, the apparent 
lactate-to-pyruvate ratio obtained from cell culture of the tumour cells used in vivo indicated that these were 
indeed highly glycolytic, and comparable to other lines that are reported in the literature as being highly glycolytic 
obtained from a variety of species. Under a reasonable set of assumptions we analytically estimated that the SNR 
reduction compared to that observed in other tissues cannot necessarily be explained on physical grounds alone, 
as we would predict that a large glycolytic flux would be observable during the perivascular growth phase of the 
metastatic colony. This was not experimentally found to be the case.
The use of ethyl-[1-13C]pyruvate as a lipophilic analogue of pyruvate has been previously proposed61. In this 
work we have further improved the limiting polarisation reached with that molecule through the use of a more 
lipophilic radical and gadolinium chelate, and additionally present the first spiral IDEAL imaging of ethyl-[1-13C]
pyruvate in the diseased brain. We clearly and unambiguously observe [1-13C]pyruvate production from 
Figure 3. Hyperpolarised 13C imaging in the porcine brain. (A–C) Example summed [1-13C]pyruvate, 
summed [1-13C]lactate and kP maps of the porcine brain post saline infusion, respectively. Here no detectable 
lactate signal is observed post bolus, with [1-13C]pyruvate appearing in the major vessels of the brain. (D–F) 
Representative [1-13C]pyruvate, [1-13C]lactate, and kP of the porcine brain post mannitol infusion, respectively. 
Here lactate exchange is observed globally, post infusion, with a similar distribution of [1-13C]pyruvate signal in 
the major vessels as seen in (A). The object seen in the posterior of the pig is the [1-13C bicarbonate] sphere used 
for transmit gain and centre frequency calibration.
www.nature.com/scientificreports/
7SCIeNTIfIC RePoRTs |  (2018) 8:15082  | DOI:10.1038/s41598-018-33363-5
ethyl-[1-13C]pyruvate in the entirety of the brain parenchyma with the same receive hardware as used previously, 
and additionally observe lactate production in the region of metastases at the three-week timepoint. However, the 
presence of the additional spectral resonances serves to make the use of spectral-spatial imaging sequences, such 
as that used for high resolution [1-13C]pyruvate imaging, challenging, owing to the reciprocal relationship 
between excitation bandwidth and the duration of the pulse. Instead, the spiral IDEAL approach used here has a 
comparatively coarse spatial resolution, but higher effective spectral resolution, and is able to spectrally, if not 
spatially, resolve the endogenous production of [1-13C]lactate in the naïve brain downstream from ethyl-[1-13C]
pyruvate. We believe that this discrepancy arises due to the multiple metabolic steps that lactate production has 
to undergo, leading to a signal at the detection limit of the technique with our hardware. We note that this appar-
ently contradicts the earlier result of Hurd et al.61, who apparently observe whole-brain lactate production 
throughout the whole brain. In comparison to the work of Hurd et al., this work was performed at higher field 
(7 T vs 3 T), resulting in a reduction in the available ⁎T2 for imaging and additionally a reduction in T1, similarly to 
pyruvate92. Ignoring differences in receive chain noise performance, our use of a 72 mm volume transmit coil 
provides greater transmit homogeneity, but the smaller receive elements used may not be equally sensitive to the 
dorsal side of the brain, which may be further expected to reduce apparent SNR from that region. We therefore 
believe that endogenous lactate production is slightly below the noise floor of this experiment, with the increased 
rate of glycolysis within the tumour being detectable.
We note that pyruvate is transported across the plasma membrane via the monocarboxylate family of 
proton-mediated transporters. There is substantial evidence to show that anaesthesia reduces both neuronal 
metabolism directly, and the rate of pyruvate transport through the brain. Both are altered under different condi-
tions such as anaesthetic dose, type, and duration93,94.
On the basis of the above experiments, we hypothesised that transportation through the BBB provided by 
monocarboxylate transporters and subsequent metabolism may be limiting for neurological studies on anaes-
thetised rodents with hyperpolarised [1-13C]pyruvate. We note that the apparent reduction in [1-13C]pyruvate 
transport across the blood-brain barrier is consistent with previous work quantifying 14C-pyruvate transport 
in the pentobarbital anaesthetised rat brain, in which it was shown to be approximately 100-fold slower than 
in the rodent heart under similar conditions (Michaelis-Menten Vmax = 0.18 μmol min−1 g−1 in the brain vs 
Vmax ≈ 10 μmol min−1 g−1 in the heart)95,96.
Figure 4. Kinetic analysis of the porcine brain. (A) Average [1-13C]pyruvate and [1-13C]lactate time course 
data from regions of interest placed in porcine brains reveals inflow and decay of the [1-13C]pyruvate signal 
post saline and mannitol. Lactate exchange is observed post mannitol infusion. Lactate normalised to peak 
[1-13C]pyruvate signal in both cases, displayed (x3) for ease of viewing. (B) Average [1-13C]lactate to [1-13C]
pyruvate ratio for all porcine experiments An increase in the exchange of [1-13C]lactate from the increased 
permeability of the blood-brain barrier is observed (*p < 0.05, effect size = 31, mean ± SD). (C) Increase in kP 
after disruption of the blood- brain barrier (*p < 0.05, effect size = 4.5, mean ± SD).
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Owing to its reported role as a neuroprotective agent, the cerebral uptake and metabolism of exogenous pyru-
vate has been substantially investigated, and it is regarded as an excellent substrate for cerebral energy metabolism 
that is predominantly metabolised by neurones97. However, both the rate of transport and the rate of utilisation of 
these substrates are reduced under anaesthesia. As differing anaesthetic regimens that alter EEG activity cause a 
linear and concomitant drop in neuronal metabolism98, the differing regimes used here – propofol and isoflurane – 
are not expected to substantially alter neuronal metabolism owing to their minimal effects on EEG activity99, 
and are consistent with “light” anaesthesia as reported previously95,100, which quantitatively does not explain this 
discrepancy alone.
However, we note that previous work has reported that the lactate to pyruvate ratio is decreased under isoflu-
rane anaesthesia of increasing depth in the brain100, heart101, and kidney102. Additionally, the lactate to pyruvate 
ratio is altered profoundly following the administration of different anaesthetic agents, with a reduction in the 
derived metabolic rate constant with increasing depth of anaesthesia from alpha-chloralose to pentobarbital103. A 
further confounding factor is that as well as altering neuronal metabolism, it is known from radiolabelled tracer 
experiments that anaesthetic regimens alter the transport of pyruvate and other metabolites into the brain, sep-
arately from altering their subsequent metabolism93. Indeed, neuronal pyruvate uptake and oxidation rates are 
altered physiologically through development and ageing amongst other processes95, and pathologically upregu-
lated following traumatic brain injury as mediated via an increase in MCT-2 expression104 as well as in cancer7.
We therefore wished to see whether our results were species-specific and confined to rodents, or if it persisted 
in larger animals scanned at clinical field strengths with comparable, but distinct anaesthetic agents. Here we have 
presented the first results of hyperpolarised [1-13C]pyruvate imaging in the anaesthetised porcine brain. Imaging 
revealed no discernible exchange of [1-13C]pyruvate to [1-13C]lactate in the naïve brain, mirroring the rodent 
case. We likewise observed the presence of [1-13C]pyruvate in the great vessels, but not in the brain parenchyma 
itself. Lactate was confined to extra-vascular spaces, and not visible in the middle cerebral artery, in contrast to 
the rat brain. However, by introducing mannitol under general anaesthesia to globally osmotically disrupt the 
blood-brain barrier we observed far greater pyruvate transport into the brain, and the clear presence of lactate 
within almost the entirety of the brain, with a clear kinetic shift in the resulting metabolic time-course, as well 
as a significant 90-fold increase in whole-brain lactate/pyruvate compared to saline injection. While the osmotic 
disruption of the BBB is not physiological, it is reversible105 and mannitol incorporation into neuronal tissue itself 
is comparatively slow compared to the lifetime of the hyperpolarised experiment106.
This procedure renders feasible the use of pigs for neurological hyperpolarised studies, undertaken using a 
clinical scanner and sequences, allowing for the translation of sequence methodology to future human studies. 
Large animal imaging on a clinical system provides a powerful tool to probe disease with similar physiological 
parameters, such as blood pressure, heart rate, and cerebrovascular perfusion. However, as shown here, it may 
be the case that the use of additional permeabilising agents (such as ultrasound or mannitol) may be required if 
hyperpolarised [1-13C]pyruvate is to adequately probe neurovascular perfusion in a pre-clinical environment. 
Future work will investigate more thoroughly the role of anaesthetic agents on cerebral metabolism as quantified 
through DNP, if possible including similar studies on awake animals adjusted previously to fMRI protocols. As 
the use of large animals provides the opportunity for serial imaging with multiple tracers, where rodent mod-
els may not tolerate extended protocols, the methods developed may provide a unique opportunity to under-
stand longitudinal alterations in cerebral metabolism (as quantified through hyperpolarised [1-13C]pyruvate and 
[2-13C]pyruvate, amongst other molecules), perfusion ([13C]-Urea), and cellular necrosis ([1,4-13C]fumarate) in 
highly relevant disease models with clinically translatable hardware.
We believe that our results can only be consistent with the explanation that BBB transportation limits hyper-
polarised [1-13C]pyruvate metabolism in anaesthetised animals. While this result apparently contradicts pre-
viously published rodent imaging work observing cerebral hyperpolarised metabolism, we note that the rat 
imaging sequence used here is able to resolve vascular structures in three dimensions, and that previous work 
using [1-13C]pyruvate has imaged models of primary brain cancer at comparatively modest spatial resolution, e.g. 
5 × 5 × 10 mm3 63, which would show a projection over much of the circle of Willis in the rat brain. Additionally, 
under these conditions, the point spread function of spectral imaging sequences is large, and Gibbs ringing and 
partial volume effects may not be neglected. In particular, the presence of a large vascular signal in the middle cer-
ebral artery combined with axial imaging orientations and the sinc-shaped artefact arising from low matrix size 
chemical shift imaging sequences may lead to a substantial degree of spatial confounding, although we cannot 
discount the hypothesis that variable responses to anaesthesia may drive differing lactate kinetics.
While it may appear that the apparent lack of adequate transport across the blood-brain barrier would limit 
the future translational applicability of the technique, we would like to note that several recently published human 
studies have performed hyperpolarised [1-13C]pyruvate imaging in the humans brain, and resolve bicarbonate 
production in vivo46,107. We hypothesise, therefore, that this study raises the question of whether or not anaesthe-
sia, or species-specific differences, are responsible for the apparent discrepancy between human and pre-clinical 
results. We note that the studies as undertaken have used two distinct anaesthetic agents, isoflurane/nitrous oxide 
and propofol/fentanyl, and observed similar limitations in both porcine and rat brain. As it has previously been 
noted that the depth of isoflurane anaesthesia has a depressing effect on hyperpolarised metabolite-to-substrate 
values in the brain and the heart in a dose-dependent fashion100,101, our work suggests that in preclincial studies 
the rate of uptake across the intact BBB is slow compared to the hyperpolarised experiment, even at the compara-
tively low isoflurane dose of 2% and under 0.4 mg/kg/h propofol anaesthesia. While we cannot assess directly the 
degree of neuronal metabolism independent of transport kinetics, the fact that mannitol permeabilisation enables 
the resolution of the hyperpolarised [1-13C]lactate signal within the brain would indicate that the hardware and 
imaging sequences we possess would enable the visualisation of neuronal metabolism were it not for the blood 
brain barrier.
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We propose, therefore, that hyperpolarised [1-13C]pyruvate imaging studies could be of greater utility in dis-
eases in which the blood brain barrier is expected to be focally disrupted, such as multiple sclerosis in which 
blood-brain barrier disruption is an early sign108. Additionally, we note that there exist ethical considerations 
that would favour the use of the technique in situations where the blood-brain barrier is already expected to be 
pathologically, and not physiologically, permeabilised. We urge preclinical researchers to consider the impact 
of pyruvate transport across the brain, quantitatively consider partial volume effects from nearby vasculature, 
and use appropriate anaesthetic agents. Further work will therefore aim to explore cerebral metabolism in disease 
with hyperpolarised MR, and additionally consider the utility of other endogenous compounds with potentially 
distinct transport kinetics, such as hyperpolarised [1-13C]lactate itself.
Methods
Rodent MRS and MRI. Animal model. Rodent experiments were carried out under appropriate personal, 
project and institutional licences granted under the UK Animals (Scientific Procedures) Act 1986, following eth-
ical review both locally by the University of Oxford Clinical Medicine Ethical Review Committee and nationally 
as part of the project license application. All experiments were conducted in accordance with the University of 
Oxford Policy on the Use of Animals in Scientific Research. For model induction, female BD-IX rats (n = 8) were 
anaesthetised with isoflurane (4% induction for approximately 1.5 min, 2% maintenance) and tumours asepti-
cally induced by stereotactic intracerebral (IC) injection of approximately 5000 ENU-1564 cells resuspended in 
PBS at 1 mm anterior, 2.9 mm left of Bregma, at 1.5 mm and 2.5 mm deep. A control contralateral injection of an 
equivalent volume of sterile PBS was also performed. The ENU-1564 cell line was chosen as a rat model of brain 
metastasis from a mammary carcinoma109–112.
Rats were housed in accordance with institutional guidelines, allowed food and water ad libitum and scanned 
only in the afternoon. During IC surgery, rats were administered with subcutaneous bupivacaine hydrochlo-
ride and adrenaline (Marcaine) for postoperative analgesia and monitored daily postoperatively for neurological 
symptoms, which were chosen to mark the humane end-point. At the last time-point animals were sacrificed via 
anaesthetic overdose (250 mg pentobarbital under isoflurane anaesthesia) followed by cardiac perfusion with 
saline and periodate lysine paraformaldehyde fixative with 0.025% w/v glutaraldehyde (PLPlight) as described 
previously109.
Immunohistochemistry. Brains were removed, fixed for a further 4–6 hours in (PLPlight), left to cryoprotect in 
30% w/v sucrose, frozen, and then sectioned. The expression of TNF type I receptors was confirmed by immu-
nohistochemistry. Briefly, frozen 10 coronal sections were cut through the brain close to the injection site; 
slides were dehydrated in ethanol and endogenous peroxidases blocked by immersion in 0.3% H2O2 in meth-
anol with general blocking provided by goat serum. Sections were stained with rabbit anti-TNF-I as primary 
antibodies (New England Biolabs, UK), using a standard protocol, and then counterstained with Cresyl Violet 
((9-dimethylamino-10-methyl-benzo[a]phenoxazin-5-ylidene)ammonium chloride; a nuclei stain). Primary 
antibodies were applied and incubated overnight. A biotinylated anti-fluorescein antibody was then applied to 
the sections, and incubated overnight before detection using a commercial “ABC” amplification system (Vector 
Laboratories, UK). The application of diaminobenamidine (Vector Laboratories, UK) in the presence of the cata-
lyst imidazole (0.01 M) evolves a dark brown colour in the presence of the primary antibody.
Rodent 13C MRS and 1H MRI. Rats were scanned weekly starting one day following surgery until the appear-
ance of any neurological symptoms, for a total of 102 observations across five weeks. Animals were anaesthetised 
in isoflurane (3% induction for approximately 1.5 min, 2% maintenance) and placed supine onto a home-built 
30 mm 13C loop coil in a home-built homeothermic small animal MR cradle and scanned on a Varian/Agilent 
7 T preclinical MRI system. Although we note that it may have been advantageous to titrate anaesthetic dose 
automatically to a target respiration rate, we found that the constant-flow anaesthetic gas system used effectively 
resulted in a mean respiratory rate of approximately 60 bpm with a standard deviation of 10 bpm. The centre of 
the coil was localised to the surgical site. T1-weighted gradient echo axial proton images were acquired (TR 120; 
50 bandwidth; TE 4.8 ms; FA 60°; 40 × 40 mm2 FOV; 192 × 192 matrix) and a multi-echo based 3D automated 
shimming algorithm used to ensure B0 homogeneity over the brain. [1-13C]Pyruvate was mixed with OX063 rad-
ical and hyperpolarised using a prototype hyperpolariser at 1.4 K, and 3.35 T/94 GHz as described previously113. 
After dissolution, 1 ml of hyperpolarised pyruvate (approximately 80 mol total dose) was injected via a previously 
placed tail vein cannula. Sagittal slice-selective spectra were subsequently obtained interleaved from both the 
contralateral and ipsilateral hemispheres of the brain with a 10 mm slice thickness, and a 1 mm gap excluding 
both the corpus callosum and middle cerebral artery. Spectra were acquired as described previously114; briefly, 
with a nominal 15° 350 μs sinc excitation, 1 s TR, 1024 complex points and a 8012 Hz spectral bandwidth. Spectral 
quantification was undertaken with the AMARES algorithm and error propagation as described previously115.
After the hyperpolarised injection, gadolinium was administered (Omniscan/Gadodiamide; 1.35 mmol kg−1) 
and an additional set of gradient-echo proton images acquired to assess tumour burden. Rat TNF was admin-
istered i.v. (60 μg kg−1; New England BioLabs, UK) and each animal allowed to recover for two hours prior to 
subsequent spectroscopy.
Hyperpolarised [1-13C]pyruvate imaging. To accurately assess the spatial distribution of hyperpolarised pyru-
vate, a separate population of rats were subject to the same surgical induction described above (n = 4) or injection 
with control vehicle (n = 4), anaesthetised and scanned weekly after IC injection. The proton protocol was the 
same as above. For hyperpolarised imaging, in order to resolve a greater spatial extent of [1-13C]pyruvate trans-
port, a dual-tuned proton/carbon 72 mm volume transmit birdcage coil was used with a two-channel 40 mm 
surface receive array with an integrated preamp. A flyback 3D spectral-spatial EPI sequence (37.5 mm slab excite; 
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64 × 64 mm2 FOV; volume 13C transmit/surface receive; TR 150 ms; TE 12.18 ms) was designed and reconstructed 
as described previously12,115 at 2 × 2 × 4 mm3. 31 mg of [1-13C]pyruvate with OX063 radical was polarized in a 
prototype hyperpolarizer for 45 minutes prior to dissolution as described previously116, and injection of 2 ml 
80 mmol pyruvate performed over 20 s via a tail vein cannula. Hyperpolarized pyruvate/bicarbonate/lactate vol-
umes were acquired interleaved (TR = 1.8 s/volume; total FA = 17°, 61°, 61°). After reconstruction, a ~2 mm3 
region of interest was drawn around the injection site by an operator blinded to the injection compound.
Cell experiments. As an in vitro control to directly measure the apparent flux through lactate dehydrogenase, 
the ENU 1564 cell line used in the in vivo experiments along with two other types of cancer cells (U251, a highly 
glycolytic glioblastoma cell line; and 4T1 cells, derived from circulating tumour cells of a mouse mammary car-
cinoma) were grown in culture. Dulbecco’s Modified Eagle Medium with 10% (v/v) FBS and 1% (w/v) glutamine 
was used as culture medium with 1% penicillin and streptomycin solution (w/v). After thawing, cells were grown 
in a T-25 flask and incubated at 37 °C until 80% confluent, before being split into a T-175 flask with 0.05% (w/v) 
trypsin. Cells were pelleted by centrifugation at 700 × g, and re-suspended in 1 mL complete medium at 37 °C in 
a warmed 1 cm diameter NMR tube.
The warmed NMR tube was then transported in a bottle of warm water to a heat bath next to a 500 MHz 
Bruker Avance spectrometer, positioned adjacent to a ‘Hypersense’ (commercially available) DNP hyperpolar-
iser. After shimming on a tube containing an equal volume of water, the cell suspensions were placed in the 
spectrometer. The dissolution was performed and the evolved liquid diluted threefold into a buffer containing 
300 μM K+-EDTA, before 1 mL was injected directly into the cell suspension. Simple pulse-acquire spectroscopy 
(hard pulse, 15° flip, TR 1 s) was then used to quantify the rate of lactate production following the injection of 
hyperpolarised [1-13C]pyruvate. Three repeats were made for each measurement obtained from three different 
culture flasks. The RF coil used was a dual-tuned proton/carbon birdcage probe, of diameter ~10 mm and length 
14 mm.
After the dissolution, the number of live cells present in the NMR tube was estimated by sampling 12.5 μL vol-
umes from the total volume, and mixing with the diazo dye Trypan Blue to differentially stain live and dead cells 
prior to automatic counting by an Invitrogen ‘Countess’ hæmocytometer. Approximately 1 × 106 to 1 × 107 cells 
were used per experiment for measurable lactate production. Spectra were temporally summed prior to quanti-
fication with AMARES as described previously115. The limit of detection for metabolic signal was approximately 
1 × 106 cells resuspended in 2 ml total volume.
To provide an approximate estimate of the expected SNR per unit cell, we wished to analytically estimate the 
difference in reception sensitivity between the in vivo and in vitro settings, and thus get a very approximate idea 
of the relative contribution of perfusion effects. For both the in vitro and in vivo case, the MR coils used are small, 
and are coil-noise dominated and not sample-noise or preamplifier shot-noise dominated. It is well-known that 
the SNR in single-coil magnetic resonance experiments scales as
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where kB is Boltzmann’s constant, R the resistance of the detection coil, T the temperature of the sample, M0 longi-
tudinal magnetisation and B1 is the receive field, assumed here through the principle of reciprocity to be equal to 
that of the transmit field117. For the high-field birdcage coil used, it is known that B1 can be expressed as118
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where l is the length of the resonator, d its diameter, I the current flowing in the coil, and ζ  a function of the rung 
spacing of the coil, which we here estimate as being approximately 0.77 based on numerical integration proce-
dures detailed elsewhere119. For the loop coil on axis, it is also well known that in the quasi-static region 
Biot-Savart provides an expression for the field as
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where r is the coil’s radius, and z the distance from the axis. Under conditions whereby a defined flip angle is 
delivered, the current that flows is limited by the amplifier power W, i.e. =I W R/ , which is typically limited by 
either the excitation bandwidth desired or the available W120. Considering geometry factors alone we calculate 
that the 30 mm loop coil is approximately a factor of 3.37 times worse in SNR for a small volume axially 10 mm 
away from the loop, i.e. the approximate distance of the tumour from the coil. Including the effects due to the 
difference in B0, we therefore end up with a very approximate statement that as M0 is independent of B0 in the 
hyperpolarised case, we should expect SNR to be ~17% on the 7 T experiments compared to those at 11.7 T. This, 
combined with an experimentally derived limit of detection of ~1 × 106 cells at 11.7 T in the 14 mm sensitive 
region of the coil provides an estimate of a minimum “detectable” tumour size of 1.48 mm3, assuming a cell den-
sity of 2.8 × 106/mm3 as experimentally derived via semi-automated cell counting on histology slides.
Hyperpolarised ethyl-[1-13C]pyruvate imaging. Owing to the increased lipophilicity of ethyl-pyruvate compared to 
pyruvate, we investigated the use of the more lipophilic AH111501 EPA radical in contrast to OX063. Ethyl-[1-13C]
pyruvate was obtained from Sigma Aldrich Ltd. (Gillingham, UK), and was prepared as neat acid doped with 15 mM 
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AH111501 “EPA” trityl radical. To 30 μl of this solution was added 5 μl of 10 mM Dotarem (Guerbet Laboratories 
Ltd) gadolinium chelate solution (2% volume-to-volume in 100% ethanol). The resulting solution was hyperpolar-
ised in a prototype DNP hyperpolariser at 93.965 GHz and 100 mW for approximately 150 minutes. Dissolution was 
performed at a pressure of 10 bar and a temperature of ~170 °C in 4.5 ml of 0.03 mM tris(hydroxyl-methyl) ami-
nomethane (TRIS) with 0.25 mM dipotassium ethylenediaminetetraacetate (EDTA) buffer solution resulting in a 
pH ~ 7 solution of approximately 54 mM ethyl-[1-13C]pyruvate. 2 mL of this solution was then injected over 20 sec-
onds via the tail vein. The time delay between dissolution and injection into the animal ranged from 20 to 25 sec-
onds. We found that the limiting solid state polarization reached by ethyl-[1-13C]pyruvate was approximately 73% of 
that of pyruvate, with a comparable liquid-state T1. A spiral multiecho sequence was designed with echo times to 
maximise the total effective number of signal averages over all metabolites (30 mm sinc excitation; 80 × 80 mm2 
FOV; 0.5 s TR; 8 echoes; = . . . . . . . .TE 1 05, 1 59, 2 13, 2 67, 3 21, 3 75, 4 29, 4 83, with a separate spectral FID 64 ms, 
FA/shot = 15°). The same volume transmit/surface receive coil hardware was used as for [1-13C]pyruvate imaging. 
Data were reconstructed by a pre-measured gradient impulse response function121 followed by NUFFT122 for a 
reconstructed resolution of . × .3 125 3 125mm2. Multicoil data was recombined via the method of McKenzie123. The 
ideal reconstruction was performed via explicit calculation of the Fourier matrix.
Porcine MRI. All porcine imaging was undertaken in accordance with the Danish Animal Welfare Act 2013 
following an explicit national ethical review process undertaken by the Danish Animal Experiments Inspectorate. 
Four healthy adult pigs (Female Danish domestic pigs, average weight 30 kg) were anaesthetised with a contin-
uous infusion of propofol (12 mg initial dose, 0.4 mg/kg/h thereafter) and a 5-French angiography catheter was 
introduced into the common carotid artery under X-ray guidance. Imaging was undertaken on a GE 3 T HDX 
clinical scanner (GE Healthcare, Waukesah, WI, USA) with subjects placed supine. Proton imaging was per-
formed with an 8 channel array coil (GE, Healthcare, USA) with a 3D T1 weighted gradient echo sequence with, 
TR = 4.9 ms, TE = 2.3 ms, FOV = 240 mm, FA = 14°, resolution = 1 × 1 × 1 mm3). 13C imaging was undertaken 
with a Helmholtz loop pair (Pulse Teq, Chobham, UK) placed anterior and posterior to the skull. Transmit gain 
and centre frequency were calibrated using a spherically symmetric 2 M 13C -bicarbonate phantom placed in the 
coils’ field of view, using a Bloch-Sigert method124.
The hyperpolarisation protocol was as described previously125, scaled proportionally for body mass: 0.64 g of 
[1-13C]-pyruvic acid (Sigma-Aldrich) was mixed with EPA (15 mM, Syncom) and was hyperpolarised in a GE 
SPINLab for approximately three hours. Two injections were administered prior to hyperpolarised imaging: a 
saline control infusion followed one hour later by mannitol. The control saline injection was undertaken as a 
300 ml bolus at 8 mL s−1 followed by a 40 ml chaser of sterile saline, and then one hour subsequently 300 ml of 
1.4 M mannitol (Sigma-Aldrich) was infused at 8 mL s−1 via the catheter to induce blood-brain barrier permeabi-
lisation, followed by a subsequent 40 ml saline flush. Sixty seconds after the end of either flush, 20 ml of 250 mM 
[1-13C]pyruvate (pH ≈ 7.5) was injected directly into the previously placed catheter (5 ml s−1). Hyperpolarised 13C 
imaging was performed using an IDEAL spiral CSI sequence with interleaved spectrum acquisition as described 
above and previously126 (axial 2D sices, TE = 1.1 ms, ΔTE = 1.1 ms, TR = 250 ms, 7 echoes and one FID, slice 
thickness = 55 mm, in-plane resolution = 6 mm2 time resolution = 2 s, total imaging time = 48 s). Imaging began 
at the end of the hyperpolarized injection.
Quantitative post processing. Dynamic images and spectra were summed in the complex domain, and 
ratiometic maps of lactate:pyruvate, were produced. Images were fitted in the frequency domain to produce kP 
maps127. A region of interest was drawn in the brain of each case, and used for average measurements of [1-13C]
lactate: [1-13C]pyruvate and kP.
Statistical analyses. Rodent statistical analyses were performed in R, with the linear mixed effects package 
lme4 used for timecourse analysis128, with Anova analysis provided through the car package129, and other pro-
cedures provided by the core features of the language. Porcine statistical analysis was undertaken in Matlab using 
the Statistics and Machine Learning toolbox, to assess for differences between pre–and post-mannitol kinetic 
results. In all cases, the conventional significance level of p < 0.05 was used, all tests were two-sided, and Cohen’s 
d effect sizes are reported where appropriate. Although we believe that linear mixed effects modelling is the most 
appropriate for the longitudinal data provided by the rodent study with each rodent being considered a random 
effect, the lack of significance reported is also found via conventional linear modelling/ANOVA or Kruskal-Wallis 
non-parametric ordinal logistic regression.
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